Several inflammation scores have shown association with survival outcomes for patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT). However, whether these scores add value to established prognostic factors remains unknown. In this retrospective, cohort study of 557 NET patients undergoing PRRT in a tertiary referral centre from 2005 to 2015, we examined inflammatory markers and scores previously associated with cancer outcomes, using Cox proportional hazard models and Akaike's information criterion. Lower albumin (hazard ratio [95% confidence interval], .91 [.87–.95] per unit), as well as higher C‐reactive protein (CRP; 1.02 [1.01–1.02]), Glasgow Prognostic Score (GPS; 1 vs. 0: 1.67 [1.14–2.44], 2 vs. 0 3.60 [2.24–5.79]), CRP/albumin ratio (1.84 [1.43–2.37]) and platelet count (Plt) × CRP, but not white blood cell, neutrophil and thrombocyte counts or derived neutrophil to lymphocyte ratio (dNLR), were associated with shorter median overall survival (OS) in an adjusted analysis. The addition of parameters based on albumin and CRP, but not dNLR, to a base model including age, chromogranin A, the cell proliferation marker Ki‐67, performance status, tumour site and previous treatments improved the predictive accuracy of the base model. In an exploratory analysis of patients with available erythrocyte sedimentation rate (ESR) and CRP, ESR emerged as the most powerful predictor. When added to a prognostic model for OS in NET patients treated with PRRT, most inflammation scores further improved the model. Albumin was the single marker adding most value to the set of established prognostic markers, whereas dNLR did not seem to improve the model's prognostic ability.

中文翻译：

---

低白蛋白血症而非衍生中性粒细胞与淋巴细胞比率 (dNLR) 可以预测接受肽受体放射性核素治疗的神经内分泌肿瘤的总生存期：一项针对 557 名患者的回顾性队列研究

一些炎症评分显示出与接受肽受体放射性核素疗法（PRRT）治疗的神经内分泌肿瘤（NET）患者的生存结果相关。然而，这些评分是否能为既定的预后因素增加价值仍然未知。在这项对 2005 年至 2015 年在三级转诊中心接受 PRRT 的 557 名 NET 患者进行的回顾性队列研究中，我们使用 Cox 比例风险模型和 Akaike 信息标准检查了先前与癌症结果相关的炎症标志物和评分。白蛋白较低（风险比 [95% 置信区间]，每单位 0.91 [0.87–0.95]），以及较高的 C 反应蛋白（CRP；1.02 [1.01–1.02]）、格拉斯哥预后评分（GPS； 1 vs. 0：1.67 [1.14–2.44]、2 vs. 0 3.60 [2.24–5.79])、CRP/白蛋白比率 (1.84 [1.43–2.37]) 和血小板计数 (Plt) × CRP，但不是白细胞在一项调整后的分析中，中性粒细胞和血小板计数或衍生的中性粒细胞与淋巴细胞比率 (dNLR) 与较短的中位总生存期 (OS) 相关。在基础模型中添加基于白蛋白和 CRP（而非 dNLR）的参数，包括年龄、嗜铬粒蛋白 A、细胞增殖标记物 Ki-67、体能状态、肿瘤部位和既往治疗，提高了基础模型的预测准确性。在对患者现有红细胞沉降率 (ESR) 和 CRP 的探索性分析中，ESR 成为最有力的预测因子。当添加到接受 PRRT 治疗的 NET 患者的 OS 预后模型中时，大多数炎症评分进一步改善了模型。白蛋白是为一组已建立的预后标记物增加最大价值的单一标记物，而 dNLR 似乎并没有改善模型的预后能力。